Clinical trial
FPA150 in Patients With Advanced Solid Tumors
NCT03514121
Study timeline
Study start (actual)2018-03-27Date precision: day
Registry last updated2024-11-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerverified · MONDO: breast cancer
Ovarian Cancerverified · MONDO: ovarian cancer
Endometrial Cancerverified · MONDO: endometrial cancer
Advanced Solid Tumorsunresolved
Interventions
FPA150BIOLOGICAL
PembrolizumabBIOLOGICAL
Sponsors & collaborators
Five Prime Therapeutics, Inc.lead sponsor
Mapped research locations
SeoulSouth Korea3Los AngelesCalifornia, United States2HoustonTexas, United States1San AntonioTexas, United States1NashvilleTennessee, United States1Oklahoma CityOklahoma, United States1DetroitMichigan, United States1New HavenConnecticut, United States1Salt Lake CityUtah, United States1ScottsdaleArizona, United States1SpokaneWashington, United States1Santa MonicaCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03514121 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.